← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
51	51 Abeona Therapeutics ABEO $266M	39	+2	+5%	$41.6M
52	52 Cellectis CLLS $111M	39	+1	+3%	$160M
53	53 Pluri PLUR $11.9M	37	0	0%	$4.6M
54	54 Opus Genetics IRD $337M	33	-2	-6%	$6.23M
55	55 DELISTED Carisma Therapeutics CARM	29	+4	+16%	$11.5M
56	56 Cartesian Therapeutics RNAC $199M	29	+13	+81%	$106M
57	57 Imunon IMNN $5.95M	26	0	0%	$4.09M
58	58 CareDx CDNA $3.45B	25	-2	-7%	$28.6M
59	59 ProQR Therapeutics PRQR $205M	25	-1	-4%	$58M
60	60 DELISTED BRAINSTORM CELL THERAPUTC BCLI	24	+2	+9%	$3.14M
61	61 Capricor Therapeutics CAPR $423M	22	0	0%	$3.34M
62	HTGM 62 DELISTED HTG Molecular Diagnostics, Inc. Common Stock HTGM	22	-1	-4%	$7.65M
63	63 Ocugen OCGN $276M	21	+5	+31%	$23.4M
64	ONCS 64 DELISTED OncoSec Medical Incorporated ONCS	21	-2	-9%	$2.8M
65	65 DELISTED BioLife Solutions BLFS	17	0	0%	$518K
66	66 Mesoblast MESO $1.81B	17	+2	+13%	$10.7M
67	67 Fulgent Genetics FLGT $587M	15	+15	–	$24.4M
68	68 Enlivex Ltd ENLV $4.46M	14	+1	+8%	$2.16M
69	PTE 69 DELISTED PolarityTE, Inc. Common Stock PTE	9	-1	-10%	$458K
70	CYAD 70 DELISTED Celyad Oncology SA American Depositary Shares CYAD	7	+1	+17%	$10.9M
71	71 Eterna Therapeutics ERNA $2.53M	7	0	0%	$2.51M
72	72 ARK Genomic Revolution ETF ARKG $2.09B	5	+1	+25%	$648K
73	73 Benitec Biopharma BNTC $295M	3	0	0%	$386K
74	74 Qiagen QGEN $9.53B	2	+1	+100%	$2.62M
75	75 DELISTED Scorpius Holdings, Inc. SCPX	1	0	0%	$644K